Biotech Values

[loridans]

Good point-- FDA Advisory does NOT mean that the FDA will approve it. It does meant that their porspects for approval dramatically increase--and investor perceptions shift to the positive--which means a good return for investors in a short time.

If the advisory panel does not recommend approval--DNDN has a longer wait to complete an ongoing 500 patient Provenge trial that would take it into 2008--most likely late 2008.